Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
21.46
+0.85 (+4.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
366,459
Open
20.37
Bid (Size)
20.15 (2)
Ask (Size)
21.59 (5)
Prev. Close
20.61
Today's Range
20.15 - 21.87
52wk Range
17.52 - 45.00
Shares Outstanding
26,562,951
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Unveiling 3 Analyst Insights On Arcturus Therapeutics
October 01, 2024
Via
Benzinga
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
September 30, 2024
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...
Via
Benzinga
Exposures
COVID-19
Performance
YTD
-35.15%
-35.15%
1 Month
+7.79%
+7.79%
3 Month
-8.21%
-8.21%
6 Month
-26.78%
-26.78%
1 Year
-6.37%
-6.37%
More News
Read More
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
September 30, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 13, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
September 03, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 27, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
Via
InvestorPlace
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 05, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
August 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 18, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
July 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
June 25, 2024
Via
Benzinga
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
June 12, 2024
Via
Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
June 10, 2024
Via
Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
June 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 07, 2024
Via
Benzinga
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
June 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
May 28, 2024
Via
Benzinga
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
May 28, 2024
Via
Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 28, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
May 15, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.